Introduction
Cholangiocarcinomas are malignancies arising from biliary tract epithelia that are increasing in incidence globally and are associated with a poor prognosis. Chronic biliary tract infection is a well-characterized predisposing factor to cholangiocarcinoma (Patel, 2006) . The inflammation-associated cytokine interleukin-6 (IL-6) is increased in bile during biliary tract infection. IL-6 is a recognized mitogen and survival factor in human cholangiocarcinoma and can contribute to tumor pathogenesis or progression (Okada et al., 1994; Meng et al., 2006b) . Targeting IL-6-mediated pathways is therefore an attractive approach to the prevention or treatment of cholangiocarcinoma. Elucidating the precise role of IL-6 in modulating cellular pathways involved in the development and progression of cancer is thus warranted.
DNA methylation is an epigenetic modification that can regulate gene expression and is tightly regulated by at least three DNA methyltransferases (DNMT-1, DNMT-3A and DNMT-3B). Aberrant DNA methylation has been implicated in many cancers (Baylin, 2005) . Global hypomethylation or aberrant hypermethylation of gene promoter CpG islands result, respectively, in tumor cell genomic instability and gene silencing, particularly of tumor suppressor genes. IL-6 has been shown to regulate the promoter activity of DNMT-1 (Hodge et al., 2001) . Elevated levels of IL-6 are associated with aberrant DNA promoter methylation, can manipulate growth regulatory pathways and can counter the effect of the DNA methylation inhibitor 5-aza-2 0 -deoxycytidine (5-aza-CdR) in decreasing both cell proliferation and anchorage-independent growth in human cholangiocarcinoma (Wehbe et al., 2006) . Moreover, IL-6-induced expression of DNMT-1 and epigenetic silencing has been associated with reduced p53 expression in multiple myeloma (Hodge et al., 2005) . Thus, regulation of expression of methylation-dependent genes is a potential mechanism by which IL-6 contributes to tumorigenesis.
Altered expression of microRNAs (miRNAs), a class of noncoding RNA, have been recently shown to be associated with human cancers. Aberrant miRNA expression in cholangiocarcinoma contributes to tumor cell proliferation and survival (Meng et al., 2006a) . However, the mechanisms by which miRNA expression is regulated in cancers are not well studied. We postulated that IL-6 can modulate miRNA expression by altering DNA methylation and asked the following questions: Does IL-6 increase DNA methylation activity in human cholangiocarcinoma? Are altered levels of miRNAs associated with IL-6 overexpression or inhibition of DNA methylation? If so, are these miRNA involved in modulation of expression of target genes involved in tumor proliferation and survival?
Results IL-6 modulates expression of DNA methyltransferases To investigate the mechanisms by which IL-6 modulates methylation-dependent gene expression, we compared the genomic response of parental (Mz-1) and IL-6 overexpressing (Mz-IL-6) cells to treatment with 5-aza-CdR using genome-wide microarray analysis. In Mz-1 cells, 5-aza-CdR treatment significantly decreased expression of the DNA methyltransferase enzyme DNMT-1 (P ¼ 0.003), as well as the putative methyltransferase HASJ4442 (Po0.001). Meanwhile, in Mz-IL-6 cells, an increased expression of DNMT-1, nicotinamide N-methyltransferase and HASJ4442 were also detected when compared to control Mz-1 cells (P ¼ 0.0019, 0.0081 and 0.0002, respectively). DNMT-1 and HASJ4442 mRNA expression was also increased in IL-6 overexpressing cells in response to 5-aza-CdR (Figure 1 ). Based on these observations, enforced expression of IL-6 can increase the overall methylation activity via a mechanism involving upregulation of expression of DNMT-1 methyltransferase.
Identification of methylation-dependent miRNAs regulated by IL-6
MicroRNA expression profiling was performed by microarray analysis in Mz-1 cells. Compared with controls, incubation with 5-aza-CdR substantially (>1.5-fold) and significantly (Po0.05) increased the expression of 77 miRNAs, representing 39.1% of the 197 miRNAs analysed. Of these, 21 unique miRNAs (10.7%) were upregulated >2-fold (Po0.01; Figure 2 ). Conversely, miRNA expression profiling in Mz-IL-6 cells identified 99 (50.3%) miRNAs whose expression was reduced o0.5-fold (Po0.05) relative to expression in control Mz-1 cells. To identify potential miRNA that were aberrantly expressed in a methylation-dependent manner by IL-6, we evaluated the 77 miRNA whose expression was modulated by 5-aza-CdR for reciprocal changes in expression with IL-6 overexpression. Thirtyfive miRNAs were not reactivated in the Mz-IL-6 cells. The expression of the remaining 42 miRNAs was thus exclusively increased by 5-aza-CdR and silenced by IL-6. Of this group, seven miRNAs were upregulated >twofold (Po0.01) by 5-aza-CdR and further significantly silenced to o 0.4-fold by overexpression of IL-6 (Po0.01; Table 1 ). This group of methylation-dependent miRNA, which can also be modulated by miR122a, .
Expression of methylation-dependent miRNA regulated by IL-6 is reduced in human cholangiocarcinoma cells We next examined the expression of this group of methylation-dependent miRNA regulated by IL-6 in both malignant MzChA-1 and KMCH-1 cells and in nonmalignant human cholangiocyte H69 and intrahepatic biliary epithelial cells (IBEC). The mature forms of (Takai and Jones, 2002) . Only one miRNA of this group, miR-370, was noted to be embedded within a CpG island. The expression of miR-370 was reduced in malignant cholangiocytes (MzChA-1 and KMCH-1) compared to that in nonmalignant cholangiocytes (IBEC; Figure 3a ). Moreover, miR-370 expression was increased by 5 mM 5-Aza-CdR in both MzChA-1 and KMCH-1 cells, but was not significantly altered in IBECs ( Figure 3b ). miR-370 expression was decreased by 72.678.3 and 91.279.8% in IL-6 overexpressing Mz-IL-6 and KM-IL-6 cells compared to their respective controls ( Figure 3c ). Furthermore, 5-Aza-CdR reduced miR-370 expression in Mz-IL-6 cells relative to control Mz-1 cells ( Figure 3d ). These results suggest that IL-6 could potentially regulate miR-370 expression by altering the methylation status of the promoter. Of note, miR-370 expression has been shown to be reduced or absent in other gastrointestinal malignancies (Bandres et al., 2006) . Interestingly, the chromosomal location of miR-370 on chromosome 14q32.31 has been noted to be deleted by loss of heterozygosity in solid tumors and several types of translocations in hematological cancers (Calin and Croce, 2006a, b) .
Enhanced miR-370 expression suppresses growth of malignant human cholangiocytes
We next explored the possible biological significance of alterations in miR-370 in malignant cholangiocytes. Cells were transfected with precursors to miR-370 to overexpress miR-370. We first verified that transfection with the miR-370 precursor would enhance mature miR-370 expression in 293T cells (data not shown). Overexpression of miR-370 decreased cell proliferation in a timedependent manner. However, transfection with control Alterations in global miRNA expression by 5-aza-CdR and by overexpression of IL-6. miRNA was isolated from control (Mz-1) and interleukin-6 (IL-6) overexpressing (Mz-IL-6) cells with or without 5-aza-CdR treatment. miRNA profiling was performed using an miRNA microarray. Samples for each pair were labeled with either Cy3 or Cy5. For each miRNA, the mean expression from eight separate determinations was obtained. For each pair, the log 2 ratio of relative miRNA expression (red versus green fluorescence intensity) was plotted for each miRNA in descending order of magnitude. The area under the curve (AUC) provides a quantitative measure of global miRNA expression. The relative expression ratios of Mz-1 þ 5-aza-CdR vs Mz-1 (a), Mz-IL-6 vs Mz-1 (b) and Mz-IL-6 þ 5-aza-CdR vs Mz-IL-6 (c) are shown. The methylation inhibitor 5-aza-CdR modestly increases overall miRNA expression. In contrast, enforced IL-6 production in Mz-IL-6 cells decreased overall miRNA expression to a greater extent, an effect which is reduced by 5-aza-CdR. (Figure 4 ).
Identification of MAP3K8 as a target for miR-370
We next screened for potential targets of miR-370 using four robust target prediction programs which use different algorithms: DIANA-MicroT (Kiriakidou et al., 2004) , TargetScan (Lewis et al., 2005) , Miranda (John et al., 2004) and PicTar (Krek et al., 2005) . All potential targets predicted by more than one of these programs were identified. Eight miRNA-mRNA target pairs were predicted by three programs, but only three pairs were predicted by all four algorithms. We selected the mitogen-activated protein kinase kinase kinase 8 (MAP3K8) for further study because of the wellcharacterized role for this gene in tumor biology. The relative expression of MAP3K8 mRNA was unchanged by either 5-aza-CdR or by overexpression on IL-6. To experimentally verify that MAP3K8 is a bona fide target of translational regulation by miR-370, several studies were performed. First, we verified that MAP3K8 is a target for miR-370 using luciferase reporter constructs containing the miR-370 recognition sequence from the 3 0 -UTR of MAP3K8 inserted downstream of the luciferase gene. Transfection with precursor miR-370 decreased reporter activity in Mz-1 cells. Next, the studies were repeated with random mutations in the recognition sequence, which resulted in abolition of the reporter activation by miR-370 precursor ( Figure 5 ). Thereafter, we assessed the effect of miR-370 expression on MAP3K8 expression. Transfection of Mz-1 cells with miR-370 precursor resulted in a 0.3470.11-fold lower expression of MAP3K8 after 3 days. Concomitant with decreased MAP3K8 expression, there was reduction of its downstream target phosphorylated p38a MAPK subunit to 0.4570.13-fold of controls (Figure 6a ). In contrast, transfection with a precursor to miR-21, which also modulates cell growth in malignant cholangiocytes, did not alter the expression of MAP3K8 with a relative expression of 1.0770.23-fold of controls. Although MAP3K8 expression is increased in malignant cholangiocytes, there was a >2-fold increase in expression of MAP3K8, along with a 152.379.7% increase in constitutive p38 MAPK phosphorylation in Mz-IL-6 cells compared to controls (Figure 6a) . 5-aza-CdR significantly reduced the expression of MAP3K8 as well as that of the proliferating cell nuclear antigen, a marker of cell proliferation, in both Mz-1 and Mz-IL-6 cells. These changes were similar to those observed with miR-370 overexpression (Figure 6b ). Taken together, these data indicate that MAP3K8 is a biologically relevant target of miR-370 and that upregulation of MAP3K8 is not a general result of promotion of cell proliferation.
MAP3K8 expression is increased after enforced expression of IL-6 in vivo Consistent with the role of autocrine IL-6 expression in tumor growth, IL-6 overexpressing (Mz-IL-6) tumor cell IL-6 modulates miRNA expression and DNA methylation F Meng et al xenografts in immunodeficient mice grow faster than control (Mz-1) cell xenografts (Meng et al., 2006b) . To determine the effect of IL-6 overexpression on modulating MAP3K8 expression in vivo, we compared kinase expression in cellular homogenates from tumor cell xenografts. Expression of MAP3K8 and phospho-p38 MAPK were significantly increased, whereas miR-370 expression was significantly decreased in homogenates from Mz-IL-6 cell xenografts compared with Mz-1 cell xenograft controls (Figure 7) . Thus increased expression of IL-6 can modulate miR-370 and increase MAP3K8 expression in vivo.
Discussion
The inflammation-associated cytokine IL-6 has been implicated in the pathogenesis and behavior of several cancers such as multiple myeloma, prostate and cholangiocarcinoma. In this study, we have identified a relationship between IL-6 and methylation-dependent regulation of miRNAs that are involved in tumor cell proliferation. There are several important implications of this work. In a broader context, cytokine-mediated epigenetic regulation of expression of nonprotein coding RNA, as well as of oncogenic kinases, provides a direct connection between cellular microenvironmental changes in inflammatory conditions and molecular events involved in tumorigenesis. This is a novel mechanism that may shed insight into the wellrecognized predisposition of chronic epithelial inflammation to neoplasia, a phenomenon that is clearly exemplified in the pathogenesis of cholangiocarcinoma. Further studies of these mechanisms may be expected to lead to either effective preventive approaches to minimize cancer development, or to effective therapeutic approaches to limit aberrant oncogene effects.
In a more specific context, these observations provide a rationale for targeting increased IL-6 production for the treatment of cholangiocarcinoma. Signal transduction activated by IL-6 can involve a multitude of pathways implicated in the pathobiology of cancers, such as the JAK/STAT pathway, the MAPK cascades, including ERK 1/2, p38 and JNK, and the PI3K/Akt pathway (reviewed in Heinrich et al., 2003) . Of these, the p38 MAPK kinase, a stress-activated protein kinase involved in cellular responses to environmental perturbations, is aberrantly activated by IL-6 in malignant, but not in nonmalignant cholangiocytes (Park et al., 1999) . Aberrant activation of p38 MAPK has been implicated in promoting tumor growth and survival and maintaining the transformed phenotype in malignant cholangiocytes and thus is highly relevant to cholangiocarcinoma (Park et al., 1999; Tadlock and Patel 2001; Yamagiwa et al., 2003; Meng et al., 2005) . Therefore, elucidating the underlying mechanisms involved in Figure 5 Identification of MAP3K8 as a target of miR-370. Mz-1 cells were plated in six-well plates, and then transfected with 1 mg of a Renilla luciferase expression construct pRL-TK and 1 mg of the pMIR-MAP3K8-wt-luc or pMIR-MAP3K8-mut-luc firefly luciferase expression construct, along with either miR-370 precursor or control precursor. Luciferase assays were performed after 48 h using the dual luciferase reporter assay system (Promega). The expression of firefly luciferase activity was normalized to that of Renilla luciferase activity for each sample. A decrease in relative firefly luciferase activity in the presence of miR-370 indicates the presence of a mir-370 modulated target sequence in the 3 0 -UTR of MAP3K8. Data represents mean7s.e. from eight separate experiments. *Po0.05.
IL-6 modulates miRNA expression and DNA methylation F Meng et al modulation of p38 MAPK by IL-6 are of considerable interest.
The observations herein provide a mechanism by which p38 MAPK can be aberrantly activated by epigenetic modulation of expression of upstream kinases such as MAP3K8. MAP3K8 was initially identified by its cellular oncogenic transforming effect Patriotis et al., 1993) . Subsequently, increased MAP3K8 expression has been reported in several human tumors such as colon, gastric, breast, nasopharyngeal carcinoma, Hodgkins lymphoma and in a hepatocellular cancer cell line (Aoki et al., 1993; Ohara et al., 1995; Sourvinos et al., 1999; Eliopoulos et al., 2002) . Recent studies using MAP3K8 knockout mice revealed that MAP3K8 plays an obligatory role in the transduction of toll-like receptor and death receptor signals that activate p38 MAP kinase and regulate the expression of cytokines, chemokines and other molecules involved in the regulation of oncogenesis and tumor growth (Chiariello et al., 2000; Banerjee et al., 2006) .
MicroRNAs are a group of nonprotein coding RNAs that are aberrantly expressed in human tumors. These IL-6 modulates miRNA expression and DNA methylation F Meng et al aberrantly expressed miRNA can modulate the expression of tumor suppressor genes as well as oncogenes. Our results indicate that IL-6 can modulate cholangiocarcinoma growth by altering the expression of the miRNA, miR-370 and associated targets such as the oncogene MAP3K8. miR-370 has been noted to be downregulated in other malignancies such as papillary thyroid carcinoma and colorectal cancer but evidence of a biological role for this miRNA has not previously been reported (Bandres et al., 2006) . Despite the observation that aberrant expression of miRNA is associated with cancer, few studies have clarified the specific role of selected miRNA or identified and validated targets for intervention. The potential of using miRNA as therapeutic targets is attractive. However, a therapeutic strategy aimed at selective tissue-specific targets may be more selective. It is therefore essential to assess the overall impact of modulation of miRNA expression on tumor behavior, and to identify and validate specific downstream targets.
Despite the significance of miRNAs in the pathobiology of cancer, the regulatory mechanisms modulating miRNA expression in tumor cells are unknown. Although chromosomal abnormalities have been associated with altered miRNA expression in some cancers (Calin and Croce, 2006b) , there is no clear association between chromosomal changes and miRNA in cholangiocarcinoma (data not shown). Saito et al. (2006) showed induction of miR-127 with reduced Bcl-2 protein expression in response to methylation and histone deacetylase inhibition, thereby demonstrating that epigenetic alterations can regulate miRNA expression. Herein, we have described epigenetic alterations in a pathophysiological context providing insight into the intricate interrelationships between cytokine signaling, DNA methylation, miRNA expression, oncogenic kinase expression and tumor biology. The repertoire of miRNA that may be regulated by epigenetic mechanisms is unknown, but we identified only a small proportion of all miRNA that could be potentially modulated in this manner. Given the tumor tissue and developmental stage specificity of miRNA, this limited group of epigenetically regulated miRNA may be expected to have a direct and specific role in tumor biology.
Therapeutic strategies to target epigenetic regulation of gene expression have been touted as anticancer therapies. Histone deacetylase inhibitors as well as DNA methylation inhibitors are being clinically evaluated for use in cancer therapy. An important implication of our studies is that the efficacy of methylation inhibitors may be limited in cancers associated with increased expression of IL-6, such as cholangiocarcinoma. A more rationale approach in such cancers would be to simultaneously target DNA methylation as well as IL-6 production or IL-6-specific molecular events. Before this, further study of the consequences of using methylation inhibitors on the expression of other methylation-dependent miRNAs and their target genes is necessary.
The clinical significance of these observations is highlighted by the definition of a mechanism by which autocrine IL-6 production can promote tumor growth as well as mechanisms by which IL-6 alters oncogene expression and aberrant kinase activity. All of these may be potentially targeted to limit tumor growth. While our studies have focused on the contribution of IL-6 to tumor growth, they provide the basis for further study to evaluate the potential role of other inflammationassociated cytokines, microenvironmental changes and epigenetic processes as modulators of miRNA expression, and in elucidation of the contribution of miRNA to other cellular effects and processes mediated by inflammatory mediators.
Materials and methods

Cells and Cell lines
MzChA-1 and KMCH-1 malignant cholangiocytes were stably transfected with full-length IL-6 to generate cell line that overexpressed IL-6 (Mz-IL-6 and KM-IL-6) relative to controls (KM-1 and Mz-1) (Meng et al., 2006b) . The basal expression of IL-6 was increased by B3-fold in Mz-IL-6 and by B1.5-fold in KM-IL-6 compared to controls. H69 and normal IBECs were obtained and cultured as previously described (Meng et al., 2006a) . To assess 5-aza-CdR effects, cells were grown to B75% confluency on 100 mm culture dishes and then treated with 5 mM 5-aza-CdR or diluent (acetic acid) controls for 24 h at 371C. Following treatment, cells were washed twice with cold phosphate-buffered saline before harvesting for isolation of genomic DNA or total protein.
Transfections
Transfections were performed using the Nucleofector system (Amaxa Biosystems, Koln, Germany) as described (Meng et al., 2006a) . Cells (1-2 Â 10 6 ) were suspended in 100 ml Nucleofector solution (Amaxa Biosystems) containing 33 ml of 100 nM miR-370 precursor or its relative control precursor (Ambion, Austin, TX, USA) at room temperature. Transfected cells were then resuspended in culture media containing 10% serum for 72 h before study. All studies were performed in quadruplicate unless otherwise specified.
Microarray analysis
Microarray analysis was performed using Affymetrix U133A plus 2 chips (Affymetrix, Santa Clara, CA, USA). Genes were considered to be altered in expression if they exhibited a minimum 1.5-fold difference in expression relative to control and they were recorded as present. Data were analysed using GeneSpring 7.0 Software (Silicon Genetics, Redwood City, CA, USA).
Isolation of miRNA
Total RNA was obtained from cell lines and tissue samples using the Totally RNA isolation kit (Ambion). The miRNA fraction was obtained using the flashPAGE Fractionator System (Ambion) as previously described (Meng et al., 2006a) . The size of the miRNA fractions were verified using an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA).
MicroRNA array hybridization and analysis
The isolated miRNAs were 3 0 -end labeled with either Cy3 or Cy5. Hybridization to glass slide-based miRNA arrays, scanning and analysis was performed as described previously IL-6 modulates miRNA expression and DNA methylation F Meng et al (Meng et al., 2006a) . Cluster analyses were performed by using MultiExperiment Viewer software (Saeed et al., 2003) .
Cell proliferation
Cells were seeded into 96-well plates (10 000 cells/well), and incubated in a final volume of 200 ml medium. Cell proliferation was assessed as previously described using CellTiter 96Aqueous (Promega Corp., Madison, WI, USA) (Park et al., 1999) .
Luciferase reporter vector
Firefly luciferase reporter vectors with the intact putative miR-370 recognition sequence from the 3 0 -UTR of MAP3K8 (pMIR-MAP3K8-wt-3 0 -UTR) or with random mutations (pMIR-MAP3K8-mut-3 0 -UTR) cloned downstream of the firefly luciferase gene were constructed (Supplementary Information). Cells were co-transfected with 1 mg pMIR-MAP3K8-wt or mut-3 0 -UTR construct and 1 mg pRL-TK Renilla luciferase expression construct without or with precursor miR-370 using TransIT-siQUEST transfection reagent (Mirus, Madison, WI, USA). Luciferase assays were performed 72 h after transfection using the Dual Luciferase Reporter Assay system (Promega).
Western blotting
Protein was extracted from cultured cells or homogenized tissues, and western blot was performed as previously described (details in Supplementary Information).
Abbreviations 5-aza-CdR, 5-aza-2 0 deoxycytidine; DNMT, DNA methyltransferase enzyme; IBEC, intrahepatic biliary epithelial cells; IL-6, interleukin-6; MAP3K8, mitogen-activated protein kinase kinase kinase 8; miRNA, microRNA.
